Trend
DailyDowntrend (starting)
4 hourLeaning Bullish
1 hourBullish
15 minStrong Bullish
5 minStrong Bearish
Daily trend turns up above $72.30
Key levels
Resistance$2.94
Resistance$2.66
Support$2.17
Support$0.15
Latest news & SEC filings
ProductIncannex Healthcare doses first patient in Phase 2 IHL-42X sleep apnea study
All IXHL news →Incannex Healthcare is a drug developer focused on combination pills and psychedelic-assisted care for long-term illnesses. Its main candidate, IHL-42X, pairs dronabinol with acetazolamide to treat obstructive sleep apnea. Another program, PSX-001, uses synthetic psilocybin alongside talk therapy for generalized anxiety disorder, while IHL-675A mixes cannabidiol and hydroxychloroquine for inflammatory conditions including rheumatoid arthritis. Work is centered in Australia and the United States.
Based on the company's 10-K filed Sep 25, 2026.
Nasdaq · Healthcare
SEPT Low Target
$15.30
SEPT Mid Target
$18.00
SEPT High Target
$20.70
Analyst Consensus
$18.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IXHL.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$14.16
17
Moat Score
NONE
4/9
Piotroski Score
0.2
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
616.7%
3yr Revenue CAGR
N/A%
EPS Growth YoY
95.93%
FCF Growth YoY
-2.8%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for IXHL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:04 | $2.28 | 1,000 | $$2K | BUY |
| 20:55:17 | $2.20 | 1,000 | $$2K | SELL |
| 20:45:53 | $2.24 | 1,000 | $$2K | BUY |
| 18:32:17 | $2.22 | 1,000 | $$2K | BUY |
| 18:11:00 | $2.18 | 2,000 | $$4K | SELL |
5 dark pool trades shown · $$13K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Incannex Healthcare Inc. (IXHL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Incannex Healthcare Inc. (IXHL) is at $2.24, down 1.32% (-$0.03) at the Nov 6, 2026 close.
Latest IXHL news — Aug 25, 2026: Incannex Healthcare doses first patient in Phase 2 IHL-42X sleep apnea study
The average analyst price target for IXHL is $18.00, ranging from $18 to $18, based on 2 analysts. Latest: Alliance Global Partners initiates on Jun 8, 2026.
Analyst ratings for IXHL: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
IXHL last reported on Sep 25, 2026: EPS -$0.14 vs $0.13 expected — a miss of 207.7%.
Support: $2.17, $0.15. Resistance: $2.66, $2.94, $3.13.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Aug 25, 2026: Incannex Healthcare doses first patient in Phase 2 IHL-42X sleep apnea study